Kane Biotech Inc. (CVE:KNE) Director Marc Edwards Buys 2,000,000 Shares

Kane Biotech Inc. (CVE:KNE) Director Marc Edwards acquired 2,000,000 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were bought at an average cost of C$0.10 per share, with a total value of C$200,000.00.

Kane Biotech Stock Performance

CVE:KNE opened at C$0.11 on Friday. The firm has a market capitalization of C$14.58 million, a P/E ratio of -3.67 and a beta of 0.52. The company has a quick ratio of 0.39, a current ratio of 0.82 and a debt-to-equity ratio of 1,164.24. The company has a fifty day moving average of C$0.11 and a 200 day moving average of C$0.13. Kane Biotech Inc. has a 52 week low of C$0.08 and a 52 week high of C$0.17.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.